ORA™ reveals in world premiere its new NEPTIS® Nx3™ triple run synthesizer during SNNMI-2015

Philippeville, Belgium, June 6th 2015 / Optimized Radiochemical Applications (ORA™) today announced it is presenting as a world premiere its new NEPTIS® Nx3™ triple independent run synthesizer for an optimized and cost-effective production of FDG radiopharmaceutical.

To succeed in a highly competitive market place, commercial PET tracer centers are facing the paradigm of increasing their FDG tracer capacity in a reliable and cost-effective way, while simultaneously being able to implement new tracers without disrupting their existing operation, minimizing their need for new investment and meeting the GMP regulatory requirements.

This brings the following challenges:
•    maximize space usage of existing hotcells to install multi-tracer synthesizers
•    minimizing need for lab space upgrade
•    providing more FDG doses from a single casette setup while reducing running costs

The only possible solution to reduce total cost of ownership for generic tracer production is clearly a multiple independent run synthesizer, with a fully integrated but non proprietary cassette.

With its new NEPTIS® Nx3™ triple independent run synthesizer, ORA innovates with a unique approach to increase FDG capacity and reliability, while dramatically decreasing running costs, saving space and meeting the most stringent GMP regulatory requirements.


This new model complements the already widest available range of synthesizers available on the market place today: NEPTIS® perform, NEPTIS® mosaic-RS and NEPTIS® mosaic-LC.

ORA™ is exhibiting its new NEPTIS® Nx3 triple run model at booth number #957 at the Society of Nuclear Medecine and Molecular Imaging annual meeting from 6-10 June 2015 in Baltimore, Maryland (US).

NEPTIS® synthesizers, dedicated for the production of PET radiopharmaceuticals, aimed since their inceptions to address the various challenges, different by nature, of personalized medicine, a young but rapidly advancing field of healthcare: restoring freedom for researchers with an open and flexible freedom, providing developers with a robust tool from clinical trials to commercial production, and offering producers a guarantee or reliable and repetitive performance. Additional information about NEPTIS® is available at www.neptis-vsa.com.

About Optimized Radiochemical Applications (ORA™)
ORA, an innovation-driven Belgian company based founded in 2006, is developing an extensive range of PET synthesizers for existing and new radiopharmaceuticals and collaborates with major research institutions and pharmaceutical companies worldwide. Additional information about ORA is available at www.oradiochem.eu.

©ORA Belgium, 2015. All rights reserved. PR15014
NEPTIS® is a trademark of ORA™


For immediate release

Contact: Vincent Tadino
Phone: (0032) 71 61 40 53
Email: info@oradiochem.eu

©ORA Belgium, 2015. All rights reserved. PR15014
NEPTIS® is a trademark of ORA™

Print Friendly, PDF & Email